GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » 3-Year Revenue Growth Rate

Seagen (Seagen) 3-Year Revenue Growth Rate : 25.40% (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Seagen 3-Year Revenue Growth Rate?

Seagen's Revenue per Share for the three months ended in Sep. 2023 was $3.45.

During the past 12 months, Seagen's average Revenue per Share Growth Rate was 7.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 25.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 29.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Seagen was 161.50% per year. The lowest was 6.30% per year. And the median was 29.60% per year.


Competitive Comparison of Seagen's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Seagen's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seagen's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Seagen's 3-Year Revenue Growth Rate falls into.



Seagen 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Seagen  (NAS:SGEN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Seagen 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Seagen's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Seagen (Seagen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson officer: Chief Financial Officer
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus

Should Investors Worry About Seagen Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-20-2023

Seagen Stockholders Approve Acquisition by Pfizer

By Business Wire Business Wire 05-30-2023